Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: shingles; temporary vision loss; dizziness; Extreme fatigue; body aches; nausea; This is a spontaneous report from a contactable other Healthcare professional (patient herself). This 20-year-old female patient, not pregnant, received his second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), Lot EL9265,via an unspecified route of administration in the left arm on 03Feb2021 at 02:00 PM (at the age of 20-year old) single dose for COVID-19 immunization. Relevant medical history included suspected allergy to penicillin. Historical vaccine included first dose of BNT162B2, Lot EL3248, on 13Jan2021 at 11:45 AM single dose in the left arm and recombinant human papillomavirus vaccine (GARDASIL) on 15Dec2020 dose 1 in the left arm. Concomitant medication included one a day women's Vitamins. After 2nd dose of vaccine BNT162B2, the patient experienced extreme fatigue, body aches, dizziness, and nausea. She was unable to go into work 2 days after receiving the vaccine due to temporary vision loss because of dizziness. On 21Feb2021 at 9:30 AM, a painful rash on the left side of torso and on spine had shown up. The patient went into her school doctor on 24Feb2021 and was diagnosed with shingles. The patient specified that she have never had this condition before, she was healthy and she did not have any significant stressors. The patient was treated with acyclovir due to the event. The outcome was not recovered for all events.   This is a spontaneous report from a contactable Other HCP. This 20-year-old female Other HCP reported herself that:        Report about covid vaccine: Yes Reporting type: AE  Reporter type: Patient  Age group: Adult (18-64 Years) Current age: 20  Current age unit: Years Gender: Female Is pregnant: No Medical qualification reporter: Other Health Professional Covid vaccine details: [{product=COVID 19, brand=Pfizer, lot number=EL9265, lot unknown=False, administration date=03Feb2021, administration time=02:00 PM, vaccine location=Left arm, dose number=2}, {product=COVID 19, brand=Pfizer, lot number=EL3248, lot unknown=False, administration date=13Jan2021, administration time=11:45 AM, vaccine location=Left arm, dose number=1}] Facility type vaccine: Other If other vaccine in fourweeks: Yes  Other vaccine 4weeks details:  [{other vaccine 4weeks product=Gardasil, other vaccine 4weeks vaccine date =15Dec2020, other vaccine 4weeks dose number =1, other vaccine 4weeks vaccine location=left arm}] Other medications in two weeks: One a day women's Vitamins  Adverse event:  Extreme fatigue, body aches, dizziness, and nausea following 2nd dose of the vaccine. I was unable to go into work 2 days after receiving the vaccine due to temporary vision loss because of dizziness. On 21Feb2021, a painful rash on the left side of my torso and on my spine had shown up. I went into my school doctor on 24Feb2021 and was diagnosed with shingles. I have never had this condition before, am 20 years old, and am healthy. I do not have any significant stressors.  Adverse event start date: 21Feb2021  Adverse event start time: 09:30 AM AE resulted in: [Doctor or other healthcare professional office/clinic visit] If patient recovered: Not recovered If treatment AE: Yes  AE treatment: Acyclovir prescription  If covid prior vaccination: No If covid tested post vaccination: No Known allergies: suspected allergy to penicillin Other medical history: N/A; Sender's Comments: Based on the available information and known product profile, the causal relationship between the reported temporary vision loss  together with the  reported dizziness and vaccination cannot be excluded.  The case will be assessed further upon receipt of additional information. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.